Chemiluminescence Immunoassay (CLIA) Market is set to Reach US$ 9.51 Billion at a CAGR of 5.67% from the forecast period 2023 to 2031 | Growth Plus Reports

Newark, New Castle, USA, June 23, 2023 (GLOBE NEWSWIRE) — Growth Plus Reports estimated the size of the global market for chemiluminescence immunoassay (CLIA) in 2022 to be worth US$ 5.70 billion, and it is expected that it will increase at a revenue CAGR of 5.67% to reach US$ 9.51 billion by 2031.

The global market for chemiluminescence immunoassay (CLIA) was analyzed and is expected to rise significantly in terms of revenue share during the forecast period. Chemiluminescence (CL) is the term used to describe the emission of electromagnetic radiation that results from a chemical reaction that produces light. A test that combines chemiluminescence and immunochemical reactions is called a chemiluminescence immunoassay (CLIA). 

Key Takeaways: 

• The increasing demand for sensitive and specific diagnostics is driving the market revenue share.
• Advanced technology increases the efficiency of CLIA and is driving the market demand.
• The demand for precise disease treatment is increasing the market revenue growth rapidly.

Request a Free Sample of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/chemiluminescence-immunoassay-clia-market/8844

                            Chemiluminescence Immunoassay (CLIA) Market Scope

Recent Development in the Chemiluminescence Immunoassay (CLIA) Market: 

• In June 2022, The BenchMark ULTRA PLUS system, a newly created powerful tissue staining platform, was unveiled by Roche. For use in in vitro diagnostics (IVD), the BenchMark ULTRA PLUS system is made to automatically stain microscopic slides of histological or cytological materials with specific immunohistochemistry, immunocytochemistry, or in situ hybridization chemicals.

Competitive Landscape

A list of the prominent players operating in the global market for chemiluminescence immunoassay (CLIA) includes: 

• Siemens Healthineers AG
• Danaher (Beckman Coulter Inc.)
• F. Hoffmann-La Roche AG
• Sysmex Corporation 
• Randox Laboratories Ltd.

Market Drivers and Restraints: 

The global chemiluminescence immunoassay (CLIA) market revenue is driven by advancements in technology, such as automation, miniaturization, and high-throughput platforms, and has significantly improved the efficiency and accuracy of CLIA tests. Furthermore, the rising healthcare expenditure in developed and developing countries has created a favorable environment for the CLIA market.

However, due to the specialized equipment, reagents, and expertise, CLIA is more expensive than other immunoassay techniques, restraining the market revenue growth. 

Request for Customization – https://www.growthplusreports.com/inquiry/customization/chemiluminescence-immunoassay-clia-market/8844

Market Segmentation: 

Segmentation By Product Type

Based on product type, the analyzers segment dominates the global chemiluminescence immunoassay (CLIA) market with the largest revenue share. This large revenue share of this segment is they are preferred for high throughput testing since they can handle a lot of samples in a short amount of time.

Segmentation By Application

Based on the application, the cancer segment dominates the global chemiluminescence immunoassay (CLIA) market with the largest revenue share. The significant revenue share is attributed to the rising prevalence of this cancer and the high demand for highly specific cancer diagnoses.  

Segmentation By End User 

Based on end-user, the hospital segment accounts for the highest revenue share in the global chemiluminescence immunoassay (CLIA) market due to the rising need for numerous disease diagnoses effectively, sensitively, and quickly. Furthermore, hospitals frequently have access to automated chemiluminescence immunoassay analyzers and other advanced diagnostic testing equipment.

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global chemiluminescence immunoassay (CLIA) market. Due to the huge and aging population in North America, there is a high demand for diagnostic tests, as well as a sophisticated healthcare system with these skills. 

Report Coverage 

Growth Plus Reports analyzed the global market for chemiluminescence immunoassay (CLIA) in-depth. We studied the fundamental market characteristics, significant investment sectors, regional growth analytics, revenue estimates, competing market players, and mergers and acquisitions.

 Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022)
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints
   3. Opportunities
5. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET- ANALYSIS & FORECAST, BY PRODUCT TYPE
   1. Analyzers
      1. Automated
      2. Semi-Automated
   2. Reagents
   3. Consumables
6. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET- ANALYSIS & FORECAST, BY APPLICATION
   1. Oncology
   2. Autoimmune Disorder
   3. Cardiological Diseases
   4. Infectious Disease
   5. Endocrine Disorders
   6. Others
7. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET- ANALYSIS & FORECAST, BY END USER
   1. Pharmaceutical and Biotechnology Companies
   2. Hospital and Clinical Laboratories
   3. Others

CHEMILUMINESCENCE IMMUNOASSAY MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8844

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Adenosquamous Carcinoma Treatment Market by Indication (Breast Cancer, Lungs Cancer), Treatment Regime (Monotherapy, Combination Therapy), Therapy (Chemotherapy, Immunotherapy) – Global Outlook & Forecast 2023-2031

Marine Nutraceuticals Market by Product (Omega-3 Fatty Acids, Fucoidan, Seaweeds), Application (Dietary Supplements, Pharmaceuticals), Form (Softgel Capsules, Powders, Liquid), Distribution Channel (Hypermarkets, Specialty Retail Stores) – Global Outlook & Forecast 2023-2031

Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Cortisone Acetate Market by Indication (Rheumatic Diseases, Dermatologic Conditions), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Belladonna Alkaloids Market by Type (Atropine, Hyoscyamine), Application (Gastrointestinal Disorders, Respiratory Disorders, Overactive Bladder), Route of Administration (Oral, Topical), End User (Hospitals, Pharmaceutical Companies)-Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.